308 related articles for article (PubMed ID: 30576462)
21. Defining the Longitudinal Risk of CIN 3+ for Piedimonte S; Tsang K; Jembere N; Murphy J; Karapetian T; Gao J; McCurdy B; Sacco J; Kupets R
J Low Genit Tract Dis; 2024 Jan; 28(1):7-11. PubMed ID: 37906611
[TBL] [Abstract][Full Text] [Related]
22. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302
[TBL] [Abstract][Full Text] [Related]
23. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
[TBL] [Abstract][Full Text] [Related]
24. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
[TBL] [Abstract][Full Text] [Related]
25. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
[TBL] [Abstract][Full Text] [Related]
26. Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology.
Wright TC; Stoler MH; Parvu V; Yanson K; Cooper C; Andrews J
Gynecol Oncol; 2019 Aug; 154(2):360-367. PubMed ID: 31160073
[TBL] [Abstract][Full Text] [Related]
27. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
28. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results.
Schiffman M; Vaughan LM; Raine-Bennett TR; Castle PE; Katki HA; Gage JC; Fetterman B; Befano B; Wentzensen N
Gynecol Oncol; 2015 Sep; 138(3):573-8. PubMed ID: 26148763
[TBL] [Abstract][Full Text] [Related]
29. Repeated Positive Cervical HPV Testing and Absent or Minor Cytology Abnormality at Pap Smear. What is the Next Step?
Caeiro V; Nunes S; Esteves B; Moutinho-Fonseca J
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1907-1912. PubMed ID: 34181350
[TBL] [Abstract][Full Text] [Related]
30. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
Hammer A; Demarco M; Campos N; Befano B; Gravitt PE; Cheung L; Lorey TS; Poitras N; Kinney W; Wentzensen N; Castle PE; Schiffman M
Int J Cancer; 2020 Sep; 147(6):1612-1620. PubMed ID: 32141607
[TBL] [Abstract][Full Text] [Related]
31. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303
[TBL] [Abstract][Full Text] [Related]
32. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
[TBL] [Abstract][Full Text] [Related]
33. CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings.
Ratnam S; Jang D; Gilbert L; Alaghehbandan R; Schell M; Needle R; Ecobichon-Morris A; Wang PP; Rahman M; Costescu D; Elit L; Zahariadis G; Chernesky M
Papillomavirus Res; 2020 Dec; 10():100206. PubMed ID: 32828968
[TBL] [Abstract][Full Text] [Related]
34. The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
Castle PE; Locke A; Tergas AI; Befano B; Poitras N; Shah NR; Schiffman M; Wentzensen N; Strickler HD; Clarke MA; Lorey T
Gynecol Oncol; 2021 Apr; 161(1):297-303. PubMed ID: 33454132
[TBL] [Abstract][Full Text] [Related]
35. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S50-5. PubMed ID: 23519305
[TBL] [Abstract][Full Text] [Related]
36. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management.
Cox JT
Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S15-25. PubMed ID: 16729900
[TBL] [Abstract][Full Text] [Related]
38. HPV Cotesting of Unsatisfactory Papanicolaou Tests: Implications for Follow-up Intervals.
Chen F; Hsu Lin L; Hindi I; Sun W; Shafizadeh N; Szeto O; Brandler TC; Simsir A
Am J Clin Pathol; 2023 Aug; 160(2):137-143. PubMed ID: 37052613
[TBL] [Abstract][Full Text] [Related]
39. A cohort study of cervical screening using partial HPV typing and cytology triage.
Schiffman M; Hyun N; Raine-Bennett TR; Katki H; Fetterman B; Gage JC; Cheung LC; Befano B; Poitras N; Lorey T; Castle PE; Wentzensen N
Int J Cancer; 2016 Dec; 139(11):2606-15. PubMed ID: 27509172
[TBL] [Abstract][Full Text] [Related]
40. Provider management of equivocal cervical cancer screening results among underserved women, 2009-2011: follow-up of atypical squamous cells of undetermined significance.
Watson M; Benard V; Lin L; Rockwell T; Royalty J
Cancer Causes Control; 2015 May; 26(5):759-64. PubMed ID: 25794897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
